Non-steroidal anti-inflammatory drugs use in older adults decreases risk of Alzheimer's disease mortality
| Autor: | Saturio Vega, Israel Contador, Julián Benito-León, Alberto Villarejo-Galende, Félix Bermejo-Pareja |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine NSAIDs Social Sciences Blood Pressure Alzheimer's Disease Vascular Medicine Cohort Studies 0302 clinical medicine Sociology Risk Factors Medicine Prospective Studies Prospective cohort study Cause of death Analgesics education.field_of_study Aspirin Multidisciplinary Cognitive Neurology Anti-Inflammatory Agents Non-Steroidal Hazard ratio Drugs Neurodegenerative Diseases Neurology Hypertension Female Research Article medicine.drug Cohort study Primary Hypertension medicine.medical_specialty Cognitive Neuroscience Cerebrovascular Diseases Science Population Education 03 medical and health sciences Alzheimer Disease Internal medicine Mental Health and Psychiatry Humans education Educational Attainment Aged Proportional Hazards Models Medicine and health sciences Pharmacology business.industry Proportional hazards model Biology and Life Sciences medicine.disease Comorbidity Pain management 030104 developmental biology Spain Cognitive Science Dementia Secondary Hypertension business 030217 neurology & neurosurgery Neuroscience |
| Zdroj: | PLoS ONE, Vol 14, Iss 9, p e0222505 (2019) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Alzheimer disease (AD) mortality risk in a large cohort of subjects treated or not with non-steroidal anti-inflammatory drugs (NSAIDs) is unknown. Our objective was to determine whether NSAIDs use is associated with decreased risk of AD mortality. In this prospective, population-based study (Neurological Disorders in Central Spain [NEDICES]) of 5,072 people without AD (aged 65 years and older), sociodemographic, comorbidity factors, and current medications were recorded at baseline. Community-dwelling older adults were followed for a median of 12.7 years, after which the death certificates of deceased participants were examined. 2,672 (52.7%) of 5,072 participants died, including 504 (18.9%) NSAIDs users and 2,168 (81.1%) non-users. Of the 2,672 deceased participants, 113 (4.2%) had AD as a cause of death (8 [1.6%] among NSAIDs users and 105 [4.8%] among non-users, chi-square = 10.70, p = 0.001). In an unadjusted Cox model, risk of AD mortality was decreased in NSAIDs users (hazard ratio [HR] for AD mortality = 0.35, 95% confidence interval [CI] 0.17–0.72, p = 0.004) when compared to non-users. After adjusting for numerous demographic factors and co-morbidities, the HR for AD mortality in NSAIDs users was 0.29, 95% CI 0.12–0.73, p = 0.009. Stratified analyses showed a significantly decreased risk of AD mortality with aspirin, whereas non-aspirin NSAIDs only showed a statistical trend toward significance in the adjusted Cox regression models. NSAIDs use was associated with 71% decreased risk of AD mortality in older adults. Our results support the hypothesis that NSAIDs use is a protective factor of developing AD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|